Eli Lilly and Company: Renal Insufficiency, Chronic trials
The registry lists 16 Renal Insufficiency, Chronic studies with Eli Lilly and Company as lead sponsor. 3 are open to participants now and 7 have results posted.
Phase 1 6Phase 2 5Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney FunctionNot yet recruitingNCT07924930Phase 1
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventRecruitingNCT07783802Phase 2
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)RecruitingNCT07241390Phase 3
- A Study of LY3113593 in Participants With Chronic Kidney DiseaseCompletedNCT02604160Phase 1Results posted
- A Study of LY2928057 in Hemodialysis ParticipantsCompletedNCT01991483Phase 1Results posted
- A Study of LY2409021 in Participants With Different Levels of Kidney FunctionCompletedNCT01929109Phase 1Results posted
- A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)CompletedNCT01621178Phase 3Results posted
- A Study of LY2623091 in Male and Females With Chronic Kidney DiseaseCompletedNCT01427972Phase 2Results posted
- Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium ClearanceCompletedNCT01237899Phase 1Results posted
- A Study in Participants With Diabetic Kidney DiseaseTerminatedNCT01113801Phase 2Results posted
- A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionCompletedNCT07426380Phase 1
- Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney DiseaseWithdrawnNCT06598631Phase 2
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingNCT06383390Phase 3
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Active, not recruitingNCT06297603Phase 3
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskCompletedNCT05803421Phase 3
- A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedNCT05536804Phase 2